Noonan 1998.

Methods	Study Design: Parallel RCT Randomisation: Random stated, method not described Concealment of Allocation: Not stated Double Blinding: yes Withdrawals / dropouts: Described Adverse events: Described Statistical analysis: Described Jadad Score: 3
Participants	Study site: multicentre No eligible: Not stated No randomised: 138 (33/34/35/36) No completed: 119 (30/30/31/28) Sex: Males: 84 (61%); Females: 54 (39%). Age: mean 23;29;30;26 Range: 12‐59 Diagnostic criteria for asthma: ATS Inclusion criteria: >= 12 yrs old, 6 month history asthma, documented history of allergy, FEV1 between 60 and 85% predicted, >= 15% reversability, positive PD20(methacholine) . Exclusion criteria: recent hospitalisation for asthma, corticosteroid use, oral theophylline, inhaled cromolyn, nedocromil,, smokers, significant concurrent disease,, pregnancy or lactation. Baseline severity of asthma: FEV1: 74;73;76;74 percent predicted
Interventions	1: FP (10% lecithin) 200mcg/day 2: FP (1% Lecithin) 200mcg/day 3: FP (1% Lecithin) 100mcg/day 4: Placebo (1% Lecithin) 2 puffs day Delivery device: pMDI Duration of treatment: 8 weeks Run in phase: 2 weeks Other: Albuterol and oral terfanadine as needed
Outcomes	FEV1, PEF, AHR, rescue medications, nocturnal asthma, symptoms
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised; other information not available